The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
niu pi xuan zhi liao yao tazarotene
Author(s): 
Pages: 204-205
Year: Issue:  4
Journal: World Clinical Drugs

Keyword:  Tazarotene氟轻松醋酸酯斑块型自体激素局部用药受体复合物商品名炎症细胞因子炎性疾病阿维;
Abstract: 1商品名Zorac2化学名6-[(3,4-二氢-4,4-二甲基-2H-1-苯并噻-?-6-基)乙炔]-3-吡啶羧酸乙酯3上市与开发厂商(美)Allorgan公司,1997年在德国首次上市。4药效分类维A酸受体激活剂5药理本品为选择性局部用维A酸类制剂,用于治疗轻至中度牛皮癣。治疗开始的第1周后即可观察到临床症状改善,常规治疗12周后临床疗效良好者高达65%。本品为一种前体药物,皮肤局部用药后通过酯酶迅速转换成其活性酸形式。本品与核酸维A酸受体(nuclearretlnolcacidreceptors,RARS),特别是在人类表皮中占优势的RAR。和RARS特异性结合而发挥作用。活化维A酸受体复
Related Articles
No related articles found